CADLCandel Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+17% of shares).
Rangebound, no clear trend. Oversold (RSI 20). Price is −3% vs its 200-day average.
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CADL is trading
Candel Therapeutics, Inc. is +52% over the past year while the S&P 500 is +16%: 36 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −2.5%
vs 200-day average · below trend, but not far
- RSI (14)
- 20
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 42%
Below its 52-week high
Details›
- Last close2026-10-23
- $8.01
- 1 monthS&P 500 −0.94%
- −31%
- 1 yearS&P 500 +16%
- +52%
- 5 yearsS&P 500 +86%
- −19%
- vs 50-day average$11.08
- −28%
- 52-week high
- $13.76
- 52-week low
- $4.42
- Annualised volatility
- 103%
| Year | Return |
|---|---|
| 2026 (year to date) | +42% |
| 2025 | −35% |
| 2024 | +490% |
| 2023 | −18% |
| 2022 | −77% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 2 of 5 | −5.7% |
| Feb | 5 | 2 of 5 | +5.2% |
| Mar | 5 | 1 of 5 | −12% |
| Apr | 5 | 2 of 5 | +65% |
| May | 5 | 5 of 5 | +19% |
| Jun | 5 | 1 of 5 | −8.8% |
| Jul | 5 | 1 of 5 | +0.34% |
| Aug | 6 | 5 of 6 | +11% |
| Sep | 6 | 2 of 6 | −4.8% |
| Oct | 6 | 2 of 6 | −13% |
| Nov | 5 | 0 of 5 | −8.0% |
| Dec | 5 | 4 of 5 | +29% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.